Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 13.7% in March

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 3,400,000 shares, a drop of 13.7% from the February 28th total of 3,940,000 shares. Approximately 6.2% of the shares of the stock are sold short. Based on an average trading volume of 781,700 shares, the days-to-cover ratio is presently 4.3 days.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares in the last quarter. State Street Corp boosted its holdings in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. Geode Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. lifted its position in shares of Agios Pharmaceuticals by 2.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after acquiring an additional 25,600 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Royal Bank of Canada lifted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $27.40 on Wednesday. Agios Pharmaceuticals has a fifty-two week low of $26.66 and a fifty-two week high of $62.58. The company has a 50 day simple moving average of $32.99 and a two-hundred day simple moving average of $40.58. The company has a market capitalization of $1.57 billion, a PE ratio of 2.42 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.